The methodological and reporting quality of randomized controlled trials of tyrosine kinase inhibitors for advanced differentiated thyroid cancer: Meta‐research study

• DOI: 10.1002/hed.27679
• Publication Date: 2024-02-12T10:34:53Z
• Authors: Rogério Aparecido...; Mario Augusto Fer...; Alice Matos Dal Boni; Ana Carolina Belt...; Ana Júlia Piazent...; Andrea Davedovicz...; Amanda Gonçalves ...; Fernanda Assaf Me...; Giovana de Olivei...; Giullia Neworal Fava; Isabela Santos Pouza; Izabelle Pimenta ...; Julia Gibran Laino; Letícia Barbosa d...; Ana Luiza Cabrera...
• Keywords: Blinding; Reporting bias

Abstract Introduction Clinical trials on tyrosine kinase inhibitors (TKI) treatment have shown an improvement in overall and progression‐free survival patients with advanced differentiated thyroid cancer. However, it is necessary to evaluate these studies assess methodological biases inconsistencies that may impact the effects. Objective To map quality of randomized clinical (RCTs) regarding randomization, allocation concealment, blinding, selective reporting bias. Methods RCTs assessing efficacy safety TKI for cancer were included. The search was performed MEDLINE database. included assessed adequacy steps, as recommended by Cochrane Risk Bias tool. Results Nine analyzed, which 77.7% classified low risk bias 33.3% high mean time between protocol registration study publication approximately 5.11 years. Moreover, 66.7% randomization did not specify process concealment a way would allow identification occurrences Concerning blinding participants outcome assessors, 77.8% reported adequate having bias, 11.1% had insufficient information unclear Regarding correctly, blind, 55.6% provide enough information. Conclusion Overall, predominantly at critical evaluation essential confidence estimated effect will support decision‐making preclude future flaws.